Socioeconomic burden of immune-mediated inflammatory diseases - Focusing on work productivity and disability

Journal of Rheumatology

Volumn 38, Issue SUPPL. 88, 2011, Pages 55-61

  Jacobs, Philip ^a   Bissonnette, Robert ^b   Guenther, Lyn C ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INNOVADERM RESEARCH   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Ankylosing spondylitis; Cost of illness; Inflammatory bowel disease; Rheumatoid arthritis

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; CANADA; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG RESPONSE; EMPLOYMENT STATUS; ENTERITIS; HEALTH CARE COST; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNOPATHOLOGY; MONOTHERAPY; PHYSICAL DISABILITY; PRIORITY JOURNAL; PRODUCTIVITY; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SOCIOECONOMICS; TREATMENT OUTCOME; UNITED STATES; WORK DISABILITY; ABSENTEEISM; ARTHRITIS; COST OF ILLNESS; ECONOMICS; EMPLOYMENT;

ABSENTEEISM; ARTHRITIS; COST OF ILLNESS; EFFICIENCY; EMPLOYMENT; HUMANS; INFLAMMATORY BOWEL DISEASES; SOCIOECONOMIC FACTORS;

EID: 84856012240     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110901     Document Type: Review

References (48)

1. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006 Sept;78:4-11. (Pubitemid 44360187)
2. Crohn's and Colitis Foundation of Canada. The burden of inflammatory bowel disease (IBD) in Canada. 2008. [Internet. Accessed August 4, 2011.] Available from: http://www.ccfc.ca/atf/cf/%7B282e45d9-a03a-49d1-883c- 39f4feaf7246%7D/BIBDC%20FINAL%20OCTOBER%2029TH%20EN.PDF
3. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology 2005;44:1169-75. (Pubitemid 41236026)
4. Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin 2009;25:2429-38.
5. Birnbaum H, Pike C, Kaufman R, Maynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2010;26:77-90.
6. Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C; Community Hypertension and Arthritis Project Study Team. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395-401. (Pubitemid 38453305)
7. Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003;48:3046-54. (Pubitemid 37409314)
8. Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007;34:2211-7. (Pubitemid 350076881)
9. Nugent Z, Blanchard JF, Bernstein CN. A population-based study of health-care resource use among infliximab users. Am J Gastroenterol 2010;105:2009-16.
10. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010;70:121-45.
11. Verstappen SM, Jacobs JW, Hyrich KL. Effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007;34:2126-8. (Pubitemid 350076867)
12. Birnbaum H, Pike C, Kaufman R, Cifaldi M. Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis. J Occup Environ Med 2009;51:1167-76.
13. Eberhardt K, Larsson BM, Nived K, Lindqvist E. Work disability in rheumatoid arthritis - development over 15 years and evaluation of predictive factors over time. J Rheumatol 2007;34:481-7. (Pubitemid 46364001)
14. Longobardi T, Jacobs P, Wu L, Bernstein CN. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol 2003;98:844-9. (Pubitemid 36576312)
15. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003;98:1064-72. (Pubitemid 36733768)
16. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006;213:102-10. (Pubitemid 44215193)
17. Theis KA, Murphy L, Hootman JM, Helmick CG, Yelin E. Prevalence and correlates of arthritis-attributable work limitation in the US population among persons ages 18-64: 2002 National Health Interview Survey Data. Arthritis Rheum 2007;57:355-63. (Pubitemid 46682521)
18. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25.
19. Jäntti J, Aho K, Kaarela K, Kautiainen H. Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20 year study. Rheumatology 1999;38:1138-41. (Pubitemid 29537337)
20. Sokka T, Kautiainen H, Möttönen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999;26:1681-5. (Pubitemid 29367305)
21. Barrett EM, Scott DG, Wiles NJ, Symmons DP. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology 2000;39:1403-9. (Pubitemid 32045868)
22. van den Hout WB, de Buck PD, Vliet Vlieland TP. Cost-utility analysis of a multidisciplinary job retention vocational rehabilitation program in patients with chronic arthritis at risk of job loss. Arthritis Rheum 2007;57:778-86. (Pubitemid 46932083)
23. Mancuso CA, Paget SA, Charlson ME. Adaptations made by rheumatoid arthritis patients to continue working: a pilot study of workplace challenges and successful adaptations. Arthritis Care Res 2000;13:89-99.
24. Kobelt G, Jönsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002;46:2310-9.
25. Joyce AT, Smith P, Khandker R, Melin JM, Singh A. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA. J Rheumatol 2009;36:743-52.
26. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31. (Pubitemid 34121668)
27. Boonen A, de Vet H, van der Heijde D, van der Linden S. Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review. J Rheumatol 2001;28:1056-62. (Pubitemid 32422589)
28. Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-van Mölken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429-37. (Pubitemid 34496822)
29. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001;60:353-8. (Pubitemid 32242748)
30. Mau W, Listing J, Huscher D, Zeidler H, Zink A. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 2005;32:721-8. (Pubitemid 40524707)
31. Barlow JH, Wright CC, Williams B, Keat A. Work disability among people with ankylosing spondylitis. Arthritis Rheum 2001;45:424-9. (Pubitemid 32979847)
32. Ward MM, Kuzis S. Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol 2001;28:315-21. (Pubitemid 32165140)
33. Boonen A, Chorus A, Miedema H, van der Heijde D, Landewé R, Schouten H, et al. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis 2001;60:1033-9. (Pubitemid 32989175)
34. Kobelt G, Andlin-Sobocki P, Maksymowych WP. Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol 2006;33:289-95. (Pubitemid 43209305)
35. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, et al American Academy of Dermatology Association; Society for Investigative Dermatology. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006;55:490-500. (Pubitemid 44209289)
36. Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, et al FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52:36-41. (Pubitemid 40129230)
37. Kavanaugh A. Economic issues with new rheumatologic therapeutics. Curr Opin Rheumatol 2007;19:272-6. (Pubitemid 46597465)
38. Mittendorf TDB, Sterz R, Cifaldi MA, Cifaldi MA, Kupper H, von der Schulenburg JM. Personal and economic burden of late stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology 2008;47:188-93. (Pubitemid 351168230)
39. Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al Yorkshire Early Arthritis Register Consortium. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59:1467-74.
40. Halpern MT, Cifaldi MA, Kvien TK. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry based control group. Ann Rheum Dis 2009;68:930-7.
41. Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716-22.
42. Laas K, Peltomaa R, Kautiainen H, Puolakka K, Leirisalo-Repo M. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann Rheum Dis 2006;65:924-8.
43. Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, van Vollenhoven RF. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis 2010;69:126-31.
44. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13. (Pubitemid 38182297)
45. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-9. (Pubitemid 40523539)
46. Maksymowych WP, Gooch KL, Wong RL, Kupper H, van der Heijde D. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 2010;37:385-92.
47. Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, et al. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol 2007;17:381-6. (Pubitemid 47425903)
48. Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat 2010 Oct 31 [Epub ahead of print]